Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy.
| Autor: | El Kawkgi OM; Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN., Li D; Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN., Kotwal A; Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN., Wermers RA; Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Mayo Clinic proceedings. Innovations, quality & outcomes [Mayo Clin Proc Innov Qual Outcomes] 2020 Nov 03; Vol. 4 (6), pp. 821-825. Date of Electronic Publication: 2020 Nov 03 (Print Publication: 2020). |
| DOI: | 10.1016/j.mayocpiqo.2020.07.006 |
| Abstrakt: | As immune checkpoint inhibitor drugs are being used in the treatment of some cancers, unusual adverse events are being reported, labeled as immune-related adverse events. Various endocrinopathies related to immune-related adverse events have been described, among which hypoparathyroidism is exceedingly rare. We report a case of hypoparathyroidism induced by immune checkpoint drugs, highlighting the need for awareness of this emerging complication. (© 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|